These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27371102)

  • 1. Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable?
    Griffiths UK; Bozzani FM; Chansa C; Kinghorn A; Kalesha-Masumbu P; Rudd C; Chilengi R; Brenzel L; Schutte C
    Vaccine; 2016 Jul; 34(35):4213-4220. PubMed ID: 27371102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
    Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
    Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
    Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
    Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.
    Usuf E; Mackenzie G; Lowe-Jallow Y; Boye B; Atherly D; Suraratdecha C; Griffiths UK
    Vaccine; 2014 Apr; 32(17):1975-81. PubMed ID: 24503271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.
    Ojal J; Griffiths U; Hammitt LL; Adetifa I; Akech D; Tabu C; Scott JAG; Flasche S
    Lancet Glob Health; 2019 May; 7(5):e644-e654. PubMed ID: 31000132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
    Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
    BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.
    De la Hoz-Restrepo F; Castañeda-Orjuela C; Paternina A; Alvis-Guzman N
    Vaccine; 2013 Jul; 31 Suppl 3():C80-7. PubMed ID: 23777697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
    Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
    Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of routine immunisation in Zambia.
    Schütte C; Chansa C; Marinda E; Guthrie TA; Banda S; Nombewu Z; Motlogelwa K; Lervik M; Brenzel L; Kinghorn A
    Vaccine; 2015 May; 33 Suppl 1():A47-52. PubMed ID: 25919174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustainability of pneumococcal conjugate vaccination in Ghana: a cost-effectiveness analysis in the context of donor transition.
    Ibrahim AM; Owusu R; Nonvignon J
    Front Public Health; 2024; 12():1383668. PubMed ID: 39148654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
    Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
    Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.